Interview with Dr John Hubbard, Senior Vice President & Worldwide Head of Development Operations, Pfizer
The Phacilitate Cell & Gene Therapy Forum celebrated its 10th Birthday in Washington, DC on January, 27th-29th. We marked the occasion by delivering the biggest and best event in the series' history. Building on a record attendance in 2013 (more than 350 of the most senior decision-makers in the cell therapy, gene therapy and tissue engineered product sectors) we welcomed our largest ever speaker panel to the event – more than 100 of the most influential payers, regulators, investors, big pharma cheque-writers and, of course, the leading lights of the global cell & gene therapy industry itself.
The Phacilitate Immunotherapy Forum is now staged in Washington, DC, following years of success in Barcelona. It is co-located with the highly successful and synergistic Cell & Gene Therapy Forum. The event provides an invaluable strategic snapshot - as well as practical solutions - to senior-level discovers and developers of novel active immunotherapeutic modalities including checkpoint inhibitors, adoptive T-cell therapies, other cancer vaccine technologies and oncolytic virus therapeutics – in other words, the hottest emerging biopharma innovation in the world today.
Stem Cells as Discovery & Research Tools is specifically designed to provide the strategic insights and networking opportunities required by senior decision makers from those companies that provide stem cell tools for drug discovery and cell banking services (plus stem cell therapy developers seeking to expand their business model), as well as the big pharma, mid-sized pharma and big biotech preclinical decision-makers who predominantly utilize them.
Recognized as the leader by the leaders, this is the event of choice for senior translational and clinical oncology R&D executives driving the development, registration and launch of novel cancer therapeutics of all classes, plus companion diagnostics. The Oncology Leaders Forum provides the perfect environment to 'sanity check' your own strategies whilst establishing and developing relationships with potential partners - for instance, in the burgeoning fields of immunoncology, combination therapy development or Big Data.
Discover which therapeutic modalities and targets will deliver genuine commercial success at the only translational/clinical strategy event bringing together pharma and biotech decision-makers from the autoimmune disease and inflammation fields. Find out how industry leaders are capitalizing on emerging tools and pathways to deliver more efficacious anti-inflammatory drugs with commercial potential across multiple therapeutic areas. The Autoimmune & Inflammation Leaders Forum arms attendees with strategic insights to help them effectively differentiate the next wave of therapeutics, preparing them for success in an increasingly competitive market environment.
THE meeting place for senior R&D executives from companies large and small tasked with de-risking drug development whilst driving innovation across the cardiometabolic field. Pinpoint the most promising opportunities in type 1 and 2 diabetes, obesity, diabetic complications and Dyslipidemia, and establish appropriate product profiles to efficiently and effectively demonstrate positive outcomes. The Metabolic Leaders Forum identifies for drug development executives the specific areas of greatest unmet need and opportunity in a therapeutic area which is beginning to move again in innovation terms after years of relative stagnation. It also proffers practically-applicable strategic solutions to the challenges in meeting safety and efficacy requirements for novel therapeutics.
Europe's Global Vaccine Partnering event, VAX 1-2-1 builds upon the long-standing and successful Phacilitate Vaccine Forum and Partnering for Emerging Markets event series. For a sector overburdened by 'me-too' events, VAX 1-2-1 delivers a unique new concept and opportunity, combining unmissable learning and partnering opportunities for the global industry's corporate, manufacturing and R&D executive, plus key external stakeholders including NGOs and public and private sector investors. Incorporating a wide range of novel formats and an innovative overall event layout, attendees will experience an array of environments in a single location, all of them geared to promote interaction and to put the onus on developing both the strategic insight and contacts required to drive vaccine R&D, manufacturing and commercial business models forward worldwide.
Interview with Brian Ellerman, Head, Technology Scouting and Information Science Innovation, Global R&D Strategy, Science Policy & External Innovation (S&I), Sanofi
Interview with Richard Schilsky, Chief Medical Officer (CMO), American Society of Clinical Oncology (ASCO)
Interview with Dr Alexander Precioso, Director of the Division of Clinical Trials and Pharmacovigilance, Instituto Butantan
Interview with Dr Do Tuan Dat, President & Director General, VABIOTECH